 CytoSorbents Corporation NASDAQ:CTSO, a critical care immunotherapy leader using its CytoSorb blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announces the commercial launch and immediate availability of CytoSorb in nine Latin American countries including Colombia, Argentina, Perú, Guatemala, Ecuador, Bolivia, the Dominican Republic, El Salvador, and Costa Rica. CytoSorb has been available in Panamá and Chile for many years, has recently received marketing approval in Mexico with initial sales, and is pending final registration in Brazil. CytoSorb is now distributed in a total of 65 countries worldwide. This expansion is particularly timely as Central and South American countries have become intense zones for COVID-19 transmission, according to the World Health Organization. In Latin American countries where CytoSorb is distributed, 2.1 million cases of COVID-19 have been reported to date, out of a total population of approximately 562 million, or approximately 0.4, and a mortality rate of 4.6. This compares to 2.4 million cases in the U.S. out of a total population of 331 million, or approximately 0.7, and a mortality rate of 5.1. Experts predict that COVID-19 will not stop until significant herd immunity develops with 60-70 of the world population either infected or vaccinated, suggesting the global pandemic is still in its early stages. 